Synthetic cannabinoid receptor agonists (SCRAs) are new psychoactive substances associated with acute intoxication and even death. However, the molecular mechanisms through which SCRAs may exert their toxic effects remain unclear -including the potential differential activation of G protein subtypes by CB1, a major target of SCRA. We measured CB1-mediated activation of Gαs and Gαi/o proteins by SCRAs by examining stimulation (PTX-treated) as well as inhibition (non-PTX treated) of forskolin-induced cAMP accumulation in HEK cells stably expressing CB1. Real-time measurements of stimulation and inhibition of cAMP levels were made using a BRET biosensor. We found that the maximum concentration of SCRAs tested (10 µM), increased cAMP levels 12 to 45% above that produced by forskolin alone, while the phytocannabinoid THC did not significantly alter cAMP levels in PTX-treated HEK-CB1 cells.
INTRODUCTION
The use of synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) is associated with significant morbidity and mortality compared to use of ∆ 9tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis [1, 2] . SCRAs are linked to wide range of toxic effects including seizures, agitation, hypertension, cardiotoxicity, kidney damage, and sometimes death [3, 4] . There has been a rapid increase in the number of structurally diverse SCRAs since 2010, with little known about their pharmacology and toxicology at time of identification [5] . The constant evolution of SCRA structures occurs in response to legislative restriction and development of urine drug screens for existing compounds [6, 7, 8] . A time-series of seizures (by tonnage) of NPS reported to United Nations Office on Drug and Crime [9] showed that the SCRAs dominated the synthetic NPS market over the period 2011-2017.
Many SCRAs are agonists at cannabinoid type-1 and type-2 receptors (CB1 and CB2, respectively [10] ; with the psychoactive effects attributed to the activation of CB1 [11] . We have previously described the in vitro quantitative measurement of SCRA efficacy at CB1, where all SCRAs tested showed between 20-300 fold greater agonist activity at CB1 compared to THC [12] . Cannabinoid receptors mediate downstream signalling predominantly through the Gαi/o protein family [13] ; however, under some circumstances, CB1 can also stimulate adenylyl cyclase (AC) through Gαs-proteins [14, 15, 16] . For example, blockade of canonical CB1-Gαi pathway with pertussis toxin (PTX) or sequestration of CB1-Gαi protein in the primary striatal rat neurons on co-expression with D2 results in an augmentation of cyclic adenosine monophosphate (cAMP) levels by cannabinoids, suggesting CB1 couples to Gαs [14, 15] . A recent study characterized the relationship between CB1 receptor expression and signalling, and showed that at very high receptor expression levels, the effect of CB1 activation on cAMP signalling was stimulatory, a phenotype that was reversed by systematic pharmacological knockdown at the receptor level [17] . The idea that certain SCRAs may preferentially activate different CB1 Gα subtypes is not unprecedented [18, 19, 20] ; in a study by Costain and colleagues [21] , AB-CHMINACA elicited an elevation in cAMP levels in both the absence and presence of forskolin in human embryonic kidney (HEK) cells transiently expressing CB1, suggesting an AB-CHMINACA-specific CB1-mediated activation of Gαs signalling.
The mechanism(s) through which SCRAs exert different behavioural and physiological effects remains unclear, and which pathways modulated by CB1 activation mediate the specific pharmacological effects of SCRAs is also unknown. Similarly, the question of whether these pathways are activated in a quantitatively or qualitatively similar way by SCRAs and THC is only beginning to be addressed [22] . Finally, the question of whether SCRA activity at noncannabinoid receptors is also important for their pharmacological effects is very much open [23, 24, 25] . With more than 250 SCRAs identified in the NPS market [9] , elucidation of the differential molecular mechanisms by which these compounds can exert distinct pharmacology, including their signalling via CB1, is essential for understanding their adverse effects. This study examined whether SCRAs that are representative of structural classes confirmed in patients admitted to emergency departments with presumed SCRA toxicity stimulate Gαs-like cAMP signalling via CB1. We measured the SCRA-mediated stimulation as well as inhibition of forskolin induced cAMP accumulation in HEK cells stably expressing CB1. We have observed SCRA-specific CB1-dependent activation of the two signalling pathways, but THC only coupled to inhibition, not stimulation of cAMP. While AB-CHIMINACA, previously identified as having a unique profile among SCRAs for elevating cAMP, appeared to signal, in part, through non-CB1 mechanisms.
METHODS

CB1 receptor transfection and cell culture
HEK 293 FlpIn cells with homogeneous G protein-gated inwardly rectifying K + (GIRK4) channel expression (the construction of these cells by Grimsey and colleagues will be described elsewhere) were co-transfected with pcDNA5/FRT construct encoding haemagglutinin (HA)tagged human CB1 receptor cDNA and pOG44 (Flp recombinase plasmid) using transfection reagent Fugene HD (Promega) as previously described for AtT-20 pituitary tumour cells [26] . (selection phase). Hygromycin concentration was reduced to 80 µg ml -1 beyond passage 5 (maintenance phase). Cells were grown in 75 cm 2 flask at 37 °C/5 % CO2 and passaged at 80% confluency as required. Assays were carried out on cells up to 25 passages.
Assay for cAMP measurement
Intracellular cAMP levels were measured using pcDNA3L-His-CAMYEL plasmid, which encodes the cAMP sensor YFP-Epac-RLuc (CAMYEL) as outlined in [27, 28] . Cells were detached from the flask using trypsin/EDTA (Sigma-Aldrich), and resuspended in DMEM supplemented with 10% FBS, 100 units ml -1 penicillin, and 100 µg ml -1 streptomycin. Cells were seeded in 10 cm dishes at a density of 7,000,000 such that they would be 60-70% confluent the next day. On the following day, the cells were transiently transfected with 5 µg of pcDNA3L-His-CAMYEL plasmid using the linear polyethylenimine (PEI, m.w. 25 kDa) (Polysciences, Warrington, PA, USA). The PEI/DNA complex mixture was sequentially added to the cells at the ratio of 1:6, and cells were incubated in 5% CO2 at 37 °C. Approximately 24 hours after transfection, the cells were then detached from the dish and the pellet was 
Data Analysis
Raw data are presented as inverse bioluminescence resonance energy transfer (BRET) ratio of emission at 475 nm/535 nm, such that an increase in ratio corresponds with increase in cAMP production. Area under curve (AUC) analysis was performed in GraphPad PRISM (Graph Pad Software Inc., San Diego, CA). Data were normalized to forskolin (set as 100%) over a 20 min period for each experiment. Concentration response curves were obtained by fitting fourparameter non-linear regression curves in PRISM to derive EC50 and EMAX. All final datasets passed the Shapiro-Wilk test for normality. Unless otherwise stated, the data represent mean ± SEM of at least 5 independent experiments, each conducted in duplicate. The differences between groups were tested using unpaired Student's t-test (PRISM). Statistical significance is defined as P < 0.05.
Materials
CP55940, WIN55212-2, 2-arachidonoylglycerol (2-AG), CUMYL-4CN-BINACA, and SR141716 were purchased from Cayman Chemical (Ann Arbor, MI, USA), ∆ 9tetrahydrocannabinol (THC) was from THC Pharm GmbH (Frankfurt, Germany) and was a kind gift from the Lambert Initiative for Cannabis Therapeutics (University of Sydney). PTX was from HelloBio (Bristol, UK), and forskolin was from Ascent Scientific Ltd. All the SCRAs, unless otherwise stated, were synthesized by Dr. Samuel D. Banister in the lab of Professor Michael Kassiou at Sydney University (Sydney, NSW, Australia). Chemical structure of SCRAs can be found elsewhere [12] . All the SCRAs were prepared in DMSO and stored in aliquots of 30 mM in -30 °C until needed.
RESULTS
Real-time cAMP BRET measurement of the Gαs mediated signalling of SCRAs
Using the CAMYEL assay, we measured the effect of seventeen cannabinoids (10 µM each) on the forskolin-stimulated cellular cAMP levels in HEK-CB1 cells following pre-treatment with PTX. All the SCRAs produced an increase in cAMP levels above that produced by forskolin alone (100%). Examples of raw traces are shown for some SCRAs (Figure 2 ), note that the stimulation of cAMP by SCRAs in presence of forskolin and PTX plateaued approximately after 12 min, and maintained at that level for the entire course of the assay (20 min) . The effects of SCRAs tested ranged from 12 to 45% increase in signal relative to forskolin alone. Most of the SCRAs had approximately 1.5 times higher effect than CP55940 (19%) or WIN55212-2 (18%), except for JWH-018, UR-144, AM-2201, and CUMYL-4CN-BINACA, which showed similar or lower effect ( Figure 2 ). AB-FUBINACA had up to 2.5 times higher effect than CP55940. In PTX treated cells, the endocannabinoid 2-AG (10 µM) produced an increase in forskolin-stimulated cAMP levels approximately twice that of CP55940, while the phytocannabinoid THC did not significantly alter cAMP levels in the presence of forskolin (compared to forskolin alone Figure 2 , P > 0.05).
Differential SCRAs-induced stimulation and inhibition of cAMP signalling in HEK-CB1
To assess whether there was any evidence of preferential coupling to Gαi/o over Gαs among SCRAs, we assessed the pharmacological activity (EC50 and EMAX) of a selection of the most prevalent SCRAs (JWH-018, PB-22, AB-FUBINACA, XLR-11, and 5F-MDMB-PICA), to stimulate and inhibit cAMP in HEK-CB1 cells. All SCRAs tested activated CB1 via Gαi/o (inhibitory, non-PTX treated), and Gαs (stimulatory, PTX-treated) in a concentration dependent manner ( Figure 3 ). As previously reported [29] , treatment with CP55940 and WIN55212-2 produced an immediate concentration dependent inhibition of forskolin-mediated cAMP production (pEC50 CP55940 8. We then tested if the SCRA-induced observed stimulatory effects were mediated through CB1 receptors. Pre-treatment of HEK-CB1 with SR141716A (3 μM, 5 min), a potent and selective CB1 antagonist [30] , largely prevented the subsequent SCRA (10 µM)-mediated stimulation of forskolin-induced cAMP response compared to the vehicle-treated cells (Figure 4 , P < 0.05).
Consistent with Gαs CB1-specific responses of SCRAs, pre-treatment with SR141716A also blocked the inhibitory cAMP signalling induced by SCRAs ( Supplementary Figure 1 , P < 0.05).
AB-CHMINACA has previously been reported to stimulate Gαs-like cAMP signalling pathway in a concentration dependent manner in HEK-CB1 cells [21] . Following PTX treatment, AB-CHMINACA increased cAMP levels above that of forskolin alone ( Figure 5 ) in a concentration-dependent manner, with an increase of 86 ± 21% at 30 µM. However, in cells pre-treated with SR141716A (3 μM, 5 min), the stimulatory effects of AB-CHMINACA (10 µM) was only partially inhibited, in contrast to other SCRAs tested in the present study. To confirm that this response was at least in part non-CB1-mediated, AB-CHMINACA was tested in HEK 293 wild-type (WT) cells; in these cells, AB-CHMINACA (10 µM) also produced a small increase in forskolin-stimulated cAMP accumulation ( Figure 5 , 29 ± 10%), suggesting that some of these stimulatory effects were occurring via mechanism(s) unrelated to CB1 receptor activity.
DISCUSSION
In this study, we set out to systematically characterize the ability of several SCRAs to activate Gαs and Gαi/o proteins by examining stimulation as well as inhibition of forskolin-induced cAMP accumulation in HEK cells stably expressing CB1. Assays of cAMP signalling revealed that the maximum concentration of SCRAs tested (10 µM), increased cAMP levels 12 to 45% above that produced by forskolin alone, while THC failed to increase cAMP levels, an observation consistent with the findings of Finlay et al. [17] . To further investigate the differential response of SCRA-induced activation and inhibition of cAMP production, we constructed the concentration response curves for the most prevalent group of SCRAs (JWH-018, PB-22, AB-FUBINACA, XLR-11, and 5F-MDMB-PICA); the rank order of potency of these SCRAs to stimulate Gαs-like cAMP signalling pathway was different from their activity at Gαi/o-pathway (inhibition of cAMP), suggesting that some of these drugs differentially regulate G protein coupling to CB1.
SCRA-mediated inhibition of cAMP has been extensively studied in cell models expressing cannabinoid receptors [21, 24] . Indeed, in some studies of CB1 signalling outputs, SCRAs have demonstrated Gαs-like phenotype [14, 15, 16, 17] . Initial experiments were conducted to determine whether traditional, endogenous, and synthetic cannabinoids stimulate Gαs mediated stimulation of cAMP synthesis. Our results are consistent with the previous reports, showing the greater maximal effect of 2-AG at Gαs-like CB1 signalling compared to CP55940 and WIN55212-2 [17] . We found that 3 of the 16 SCRAs tested, AB-FUBINACA, PB-22, and AB-PINACA, activated Gαs-like CB1 signalling to more than 30% above the forskolin response.
In a previous study using AB-CHMINACA, Costain and colleagues [21] showed similar increases in cAMP levels to that seen in this study without the need for FSK or PTX pretreatment. Costain et al. [21] , performed their assays on HEK293T cells transiently transfected with CB1. Transient transfection of CB1 may have led to a higher level of receptor expression than in our cells, and high levels of CB1 receptor expression is sufficient to result in a switch in cAMP signalling from Gαi-mediated (inhibitory) to Gαs-mediated (stimulatory) [17] .
Furthermore, the HEK-293 "T" subclone used in the previous study harbors considerable genomic differences to the parental HEK 293 cell line used in the present study [31, 32] , which may also contribute to altered cAMP responses (via different adenylyl cyclase isoforms).
However, our data, together with that of Costain et al. [21] suggest potentially different receptor/effector coupling pathways in the presence of some SCRAs (AB-FUBINACA, PB-22, and AB-PINACA, AB-CHMINACA) compared to other CB1 ligands.
We further sought to investigate SCRA differential activation of distinctive G protein subsetsinhibition and stimulation of forskolin-mediated cAMP signalling. The relative ability of SCRAs to induce inhibition of cAMP production via Gαi/o is very similar to that observed in previous studies in assays of membrane potential and [ 35 S]GTPγS binding [12, 25, 33, 34] . The similar EMAX observed for the SCRA-mediated activation of Gαi/o-CB1 signalling probably reflects receptor reserve for inhibition of cAMP accumulation in these cells, wherein maximal responses are elicited at less than maximal receptor occupancy because the system maximum is already achieved [12] . SCRA-induced stimulation of cAMP showed significant differences in EMAX (Table 1 ), suggesting lower levels of receptor reserve for SCRAs coupled to Gαs protein. This may (at least for the drugs with a lower EMAX) reflect an accurate representation of intrinsic efficacy of the ligands at this pathway [35] . The observed dynamic range of EMAX for cannabinoids is consistent with CB1 having low coupling efficiency to both Gαs-pathway and β-arrestin-2 (as observed previously; [32] , compared to that of Gαi-pathway [17, 36, 37] . Future studies could examine the structure of SCRA-bound CB1-Gαs complexes, which might assist in explaining the observed cAMP signalling profiles. This is particularly interesting given that the interaction of SCRA MDMB-FUBINACA with the "toggle twin switch" in the CB1 binding pocket coupled to Gαi was recently studied [38] . The rigid C-shape geometry of MDMB-FUBINACA along with the strong pi-pi interaction of its indazole ring with "toggle twin switch" residues, might help distinguish the high efficacy agonist activity of SCRA from partial agonists like THC lacking "toggle twin switch" interaction [38] . Promiscuous coupling to both Gαi and Gαs has been reported for multiple GPCRs (e.g. β2-adrenergic receptor) [39] , while some receptors couple pre-dominantly to one G protein subtype (e.g. μ-opioid receptor coupling to the Gαi/o family, [40] ). The potential of cannabinoids to differentially activate one signalling cascade over another (functional selectivity, [41] ) may aid the development of new therapeutic compounds with reduced psychoactive effects; a research domain that has attracted much recent interest [42] .
Considering the adverse effects associated with SCRA use, it is important to continue characterizing the pharmacological profile of these compounds in order to understand the mechanisms driving their toxicity [43, 44] . Although this study does not identify which pathway contributes to the toxic effects observed following SCRA consumption, our data do provide valuable insights into SCRA-mediated stimulation and inhibition of cAMP signalling in vitro. Previous studies have shown that JWH-018-AM-2201-, 5F-AB-PINACA-, and CUMYL-4CN-BINACA-induced seizures are CB1-mediated in mice, which might explain some of the toxicity experienced by recreational users of these drugs [43, 44, 45, 46, 47, 48, 49] . Our data shows that SCRA-induced cAMP increase was abolished after SR141716A treatment, supporting the hypothesis that SCRAs Gαs-like effects were mediated through CB1
receptor. All the SCRAs tested in this study exhibited greater potency at Gαi-than Gαs-like pathways, and the efficacies of these SCRAs have previously been measured in response to Gαi-mediated activation of GIRK channel in AtT20-CB1 cells [12] . The rank order of SCRA efficacy based on selectivity for Gαi-GIRK signalling was found to be 5F-MDMB-PICA > XLR-11 > AB-FUBINACA > PB-22 ≈ JWH-018 [12] . 5F-MDMB-PICA showed the highest efficacy for modulation of K channel activity via Gαi-pathway in the former study, in contrast to the intermediate efficacy of 5F-MDMB-PICA to stimulate the Gαs-like cAMP signalling pathway in the present study. AB-FUBINACA exhibited greater efficacy for the Gαs-pathway compared to its Gαi-mediated activity profile in the membrane potential assay [12] . Evaluating the differences in G protein preference between SCRAs may be an important part of understanding the apparent differences in effect between these drugs in humans.
Our study showed that SCRAs have significantly different pharmacological profiles (maximal activities and potencies) for the activation of CB1-G protein-stimulation and -inhibition of forskolin-mediated cAMP signalling. Although it is speculated that the adverse effects of SCRAs are mediated by CB1 [49, 50] , based on the results presented here we wonder how the differential responses of SCRAs are related to the physiological effects resulting from the activation of each intracellular pathway, and if these may be correlated with the in vivo toxicity of SCRAs. The unique toxicological profile of SCRAs may result from a combination of factors; pharmacokinetic differences, activity at both cannabinoid and non-cannabinoid targets, pharmacological activity of metabolites and thermolytic degradants [25, 37, 51, 52] . These findings may provide a starting point to help predict the pharmacological characteristics of SCRAs that demonstrate differential activation of Gαi versus Gαs coupling to CB1. Table 1 Comparison of pharmacological activity (EC50 and EMAX) of SCRAs-induced stimulation (Gs (+PTX)) and inhibition (Gi (-PTX)) of cAMP signalling in HEK-CB1 cells. The selectivity is expressed as the ratio of Gs (+PTX) EC50 to Gi (-PTX) EC50.
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